Maria de Toledo

Maria de Toledo

Auto-generated profile, based on publicly available information

Maria de Toledo

Epilepsy Program, Neurology Department Hospital Universitario La Princesa Madrid Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2009 in Journal of Geriatric Psychiatry and Neurology
Verified
Journal Article
Closed access
FBF. Bermejo-Pareja
F. Bermejo-Pareja
JBJulián Benito-León
Julián Benito-León
SVS. Vega
S. Vega
JOJ. Olazarán
J. Olazarán
MTM. de Toledo
M. de Toledo
GRG.C. Román
G.C. Román
Background: Few longitudinal studies have verified the clinical diagnosis of dementia based on clinical examinations. We evaluated the consistency of the clinical diagnosis of dementia over a period of 3 years of follow-up in a population-based, cohort study of older people in central Spain. Methods: Individuals (N = 5278) were evaluated at baseline (1994-1995) and at follow-up (1997-1998). The evaluation included a screening questionnaire for dementia and a neurological assessment. Results: Dementia screening consisted of a 37-item version of the Mini-Mental State Examination (MMSE) and the Pfeffer Functional Activities Questionnaire (FAQ). Study neurologists investigated those participants who screened positively (N = 713) as well as 843 who had screened negatively to test the sensitivity of the screening instruments or because they had a positive screening for other chronic neurological diseases. We detected 295 patients among those who screened positive and 13 among those who screened negatively. Three years follow-up evaluation demonstrated 14 diagnostic errors at baseline (4.5%) leading to a final number of 306 patients with dementia. The corrected prevalence of dementia was 5.8% (95% confidence interval [CI] 5.2-6.5). Conclusions: The diagnosis of dementia was highly accurate in this population-based, Spanish cohort study, and our prevalence figures agree with other European surveys. Given the high cost and difficulties of population rescreening and its relatively low yield, we conclude that a single 2-phase investigation (screening followed by clinical examination) provides accurate information for most population-based prevalence studies of dementia.

1 January 2004 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
FJFélix Javier Jiménez-Jiménez
Félix Javier Jiménez-Jiménez
IPInmaculada Puertas
Inmaculada Puertas
MTMaria de Toledo-Heras
Maria de Toledo-Heras

12 June 2007 in European Neurology
Verified
Journal Article
Closed access
FJFélix Javier Jiménez-Jiménez
Félix Javier Jiménez-Jiménez
MTMaría de Toledo-Heras
María de Toledo-Heras
HAHortensia Alonso-Navarro
Hortensia Alonso-Navarro
LALucía Ayuso-Peralta
Lucía Ayuso-Peralta
JAJuan Arévalo-Serrano
Juan Arévalo-Serrano
BBBeatriz Barcenilla
Beatriz Barcenilla
We conducted a case-control study searching for a possible role of environment in the risk of essential tremor (ET). We interviewed 142 ET patients and 284 age- and sex-matched controls about a family history of ET, exposure to environmental products containing lead, mercury, manganese, solvents and β-carbolines, and exposure to agricultural work, well water, pesticides, and cigarette smoking and alcohol drinking habits. In a univariate study, reported family history of ET and exposure to agricultural work, pesticides, smelting, frosted glass, paintings, wheat, corn, and barley were more frequent in the ET patient group. With a multivariate study, only reported family history of ET and exposure to agricultural work and frosted glass remained significant. Time of exposure to agricultural work, wheat and barley was significantly higher in ET patients. Age at onset of ET was significantly lower in patients with a family history of tremor and higher in patients exposed to iron-manganese alloys and alcohol. Time of exposure, but not total consumption of alcohol and cigarettes, was correlated with age at onset of ET. In conclusion, our study shows that the association between ET and reported family history of ET was robust, and that there were also associations between ET and exposure to some environmental factors (agricultural work and frosted glass).

1 July 2000 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
AGAngel Berbel Garcia
Angel Berbel Garcia
AIAdela Latorre Ibarra
Adela Latorre Ibarra
Jesus Porta EtessamJesus Porta Etessam
Jesus Porta Etessam
ASAntonio Martinez Salio
Antonio Martinez Salio
DMDavid Andres Perez Martinez
David Andres Perez Martinez
MHMaria Toledo Heras
Maria Toledo Heras
Neurologic manifestations of HIV infection are quite diverse and can develop into seizures. Because new drug therapies have been developed, it is important to know the interactions between antiretroviral and antiepileptic agents. A 36-year-old patient with HIV developed a set of progressive left hemiparesis and secondarily generalized partial seizures related to progressive multifocal leukoencephalopathy. Phenytoin and carbamazepine were necessary to control the seizures. Instead of diverse antiretroviral therapies, the viral load was increased. Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity. Carbamazepine was discontinued and the patient remained asymptomatic. The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir. Ritonavir is a potent inhibitor of hepatic cytochrome P450, mainly the CYP3A4 isoform. Carbamazepine is metabolized by this subsystem. Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity. We present a case of interaction between ritonavir and carbamazepine. Interaction between antiepileptic and antiretroviral agents is an emergent problem caused by the increasing association of the two therapies. We recommend strict monitoring of serum antiepileptic drug (AED) levels to avoid toxicity and inadequate seizure control.

1 June 2004 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
AGAngel berbel garcia
Angel berbel garcia
Jesus Porta EtessamJesus Porta Etessam
Jesus Porta Etessam
AMAntonio Martinez-Salio
Antonio Martinez-Salio
JMJose Maria Millan-Juncos
Jose Maria Millan-Juncos
DPDavid A. Perez-Martinez
David A. Perez-Martinez
MTMaria Toledo-Heras
Maria Toledo-Heras
We describe clinical, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) findings in a patient with general paresis. MRI demonstrated cortical–subcortical atrophy and broad-coalescent high-intensity T2 lesions in right frontotemporal lobes. After intravenous penicillin therapy, the size of these lesions diminished dramatically. That regression correlated with improvement in neuropsychologic test and CSF analysis. To our knowledge, this is the first case reported in the literature of MRI-reversible lesions in a patient with general paresis. We suggest that MRI is of prognostic value in patients with general paresis. Severe atrophy, especially in the temporal lobe, could be a marker of bad clinical outcome.

29 June 2016 in Epileptic Disorders
Verified
Journal Article
Closed access
IGIñigo Garamendi‐Ruiz
Iñigo Garamendi‐Ruiz
MGMaría Eugenia García‐García
María Eugenia García‐García
VBVicente Bertol‐Alegre
Vicente Bertol‐Alegre
JMJosé Ángel Mauri‐Llerda
José Ángel Mauri‐Llerda
IGIrene García‐Morales
Irene García‐Morales
AMAinhoa Marinas‐Alejo
Ainhoa Marinas‐Alejo
Perampanel, a non‐competitive antagonist of the α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptors, is the most recent antiepileptic drug available in Spain, marketed in January 2014. It was initially approved by the European Medicines Agency as adjunctive treatment for partial‐onset seizures in patients 12 years and older, but recently also for primary generalized tonic‐clonic seizures. Although clinical trials provide essential information about the drug, they do not reflect daily clinical practice. This retrospective study shows the initial experience with perampanel in 11 Spanish hospitals during its first year post‐commercialisation. All patients who started perampanel treatment were included, but efficacy and tolerability were only assessed in those patients with a minimum follow‐up period of six months. In total, 256 patients were treated with perampanel before September 2014, and 253 had an observational period of one year. After six months, 216/256 patients (84%) continued on perampanel and 180/253 (71.1%) completed one year of treatment. The mean number of previous antiepileptic drugs used was 6.83 and the median number of concomitant antiepileptic drugs was 2. The mean perampanel dose was 7.06 mg and 8.26 mg at six and 12 months, respectively. The responder rate was 39.5% and 35.9% at both follow‐up points, respectively. Adverse events were experienced by 91/253 (35.5%) and resulted in withdrawal in 37 (14.6%). The most common adverse events were somnolence, dizziness, and irritability. We found no significant differences between concomitant use of enzyme‐inducing and non‐inducing antiepileptic drugs, regarding efficacy, adverse effects, or withdrawals. Irritability was not influenced by concomitant use of levetiracetam, relative to other drugs, but was more frequently observed in patients with a history of psychiatric problems or learning disabilities.